In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alnylam Europe AG

Division of Alnylam Pharmaceuticals Inc.

Latest From Alnylam Europe AG

Recent Dealmaking (9/2003)

Summarizing the month in European dealmaking.

Gene Expression Technologies Ltd.

Gene Expression Technologies Ltd. (GET) aims to use its novel Gene Inactivation by Chromatin Engineering (GeneICE) platform to achieve complete and accurate gene silencing, while maintaining the flexibility and speed embodied by RNAi and antisense technologies currently used for silencing-based drug target validation. GET's GeneICE constructs are also being tested as potential therapeutics.

BioPharmaceutical Europe

RNAi Revs Up

Scientists have recently recognized an apparently fundamental cellular mechanism that may be a sort of ancient immune system. Called RNAi, for RNA interference, the process utilizes pieces of double-stranded RNA to prevent gene expression. RNAi has quickly become a powerful research tool, but its real promise lies in its potential to generate a brand-new class of highly specific medicines. Researchers have only just begun to explore how RNAi works in mammalian cells, so there's no telling if it actually will give rise to therapeutics. A growing number of companies are betting they'll be able to turn the fad into fortunes. Already, some of the challenges to commercialization are obvious: how to deliver the RNA, and who if anyone will control intellectual property rights. Some firms aim to directly deliver short sequences of RNA, and those who travel this route may confront challenges similar to those faced by antisense companies. Others are trying gene therapy approaches and will inherit all the problems of that field. As in any new field, bluster and blather are mixed with secrecy about who has what in terms of technology, money, and patents. The winner is likely to be the first company that can reduce concept to practice, and come up with a drug that works.

BioPharmaceutical Strategy

No Nonsense Drug Discovery

For such an apparently well-understood molecule, it's certainly taken enough time for RNA to become a focus of drug discovery. But increasingly, it's the new, hot target. Companies focusing on or around RNA are multiplying. One of the best funded of the new companies is PTC Therapeutics, with $56 million raised so far. PTC is creating a platform around the post-transcriptional modulation of RNA, aiming to increase or decrease gene expression by tinkering with the mechanics of how RNA makes proteins.

BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ribopharma AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Alnylam Pharmaceuticals Inc.
  • Senior Management
  • Roland Kreutzer , PhD, CEO
    Ulrich Bodner, PhD, VP, Bus. Dev.
    Stefan Limmer, PhD, CSO
    Andreas Bossko , VP, Fin.
  • Contact Info
  • Alnylam Europe AG
    Phone: (49) 922 182 7620
    Fritz-Hornschuch-Str. 9
    Kulmbach, 95326